What are the indications of fezolinetant and introduction to the applicable patient population?

Fezolinetant (Fezolinetant) is a new type of selective neurokinin receptor antagonist, mainly used to treat moderate to severe menopausal hot flashes in postmenopausal women. Menopausal hot flashes are a common symptom that many women experience before and after menopause, manifesting as sudden heat sensation, sweating, and palpitations, which seriously affect their quality of life. Fezonatant relieves the symptoms of hot flashes by regulating the thermoregulatory mechanism of the central nervous system, making it an innovative therapeutic drug in this field.

Fezonatant is mainly suitable for postmenopausal female patients who experience moderate to severe hot flashes, especially those who are unable or unwilling to use hormone replacement therapy (HRT). Fezonatant provides a safe and effective alternative for patients who are at risk for hormone-related diseases, have a history of breast cancer, or are otherwise contraindicated in the use of hormone therapy.

Clinical trials have shown that filazonatant can significantly reduce the frequency and severity of hot flashes and improve patients' sleep quality and daily life. Compared with traditional hormone therapy, fizonatant does not involve direct regulation of hormone levels, so it has excellent safety performance, does not increase hormone-related risks, and is suitable for long-term management of menopausal symptoms.

Although filazonatant is a non-hormonal drug with good safety, patients still need to follow the doctor's advice during use and pay attention to possible side effects such as headache, fatigue, etc. In the future, with the accumulation of more clinical data, fezonatant is expected to expand its scope of application and become a routine treatment option for menopausal women to relieve various symptoms and help improve patients' quality of life.

Reference materials:https://www.drugs.com/